PUBLISHED ON |
05 September 2018
05 September 2018
SGX has one of the world’s most market-oriented and efficient suite of capital-raising processes for companies. The comprehensive suite of offerings includes IPOs, rights and bonus issues, stock splits and consolidations, private placements, as well as takeovers.
Singapore’s healthcare sector is seen as defensive, with strong valuations, and poised to enjoy multi-year growth prospects. Drivers of Asia’s increased healthcare spending levels include accelerated ageing rates, the rise of lifestyle diseases, and growing disposable incomes.
From 2013 to 1H 2018, healthcare stocks on SGX raised a total of US$1 billion from 16 listings (total US$211 million raised), 25 equity placements and rights issues (total US$213 million raised), and nine bond listings (total US$550 million raised).
SGX has one of the world’s most market-oriented and efficient suite of capital-raising processes for companies. The comprehensive suite of offerings includes IPOs, rights and bonus issues, stock splits and consolidations, private placements, as well as takeovers.
Singapore’s healthcare sector is typically viewed as a defensive segment with strong valuations, poised to enjoy multi-year growth prospects. Drivers of Asia’s increased healthcare spending levels include accelerated ageing rates, the rise of lifestyle diseases, and growing disposable incomes.
Frost & Sullivan estimates that the Asia-Pacific healthcare industry will expand by 11.1% to US$517 billion in 2018, representing one of the fastest growing regions worldwide, compared with an average 4.8% growth rate for the global healthcare sector.
The listed healthcare sector in Singapore, as tracked by the benchmark SGX All-Healthcare Index, comprises companies that operate in the segments of pharmaceuticals and biotechnology, healthcare and patient services, as well as medical equipment and supplies.
Between 2013 and 1H 2018, healthcare stocks on SGX raised a total of US$1 billion from the following activities:
- 16 listings US$211 million raised
- 25 equity placements and rights issues US$213 million raised
- 9 bond listings US$550 million raised
Note that the above figures exclude secondary funds of US$2.3 billion raised by Lonza Group in February and May 2017, and nine bond issuances of US$1.4 billion by privately held companies between 2013 and 1H 2018.
The capital-raising activities conducted by healthcare companies on SGX in the 2018 year-to-date and calendar year 2017 are listed below, sorted by date.
The tables below detail SGX’s recent healthcare listings, sorted by market capitalisation.
Did You Know?
The SGX All-Healthcare Index is a free-float, market capitalisation-weighted index that comprises 31 constituents with a combined market capitalisation of about S$35 billion. Seven of the 10 largest constituents of the Index report more than a third of group revenues to Asia Pacific ex-Singapore, namely Southeast Asia, North Asia and South Asia.
This article is provided by SGX My Gateway.
SGX My Gateway
SGX's investor education portal with market, product and investment information and events. Sign up now at sgx.com/mygateway to receive our investment updates and economic calendar.
This document is not intended for distribution to, or for use by or to be acted on by any person or entity located in any jurisdiction where such distribution, use or action would be contrary to applicable laws or regulations or would subject Singapore Exchange Limited (“SGX”) to any registration or licensing requirement. This document is not an offer or solicitation to buy or sell, nor financial advice or recommendation for any investment product. This document is for general circulation only. It does not address the specific investment objectives, financial situation or particular needs of any person. Advice should be sought from a financial adviser regarding the suitability of any investment product before investing or adopting any investment strategies. Use of and/or reliance on this document is entirely at the reader’s own risk. Further information on this investment product may be obtained from www.sgx.com. Investment products are subject to significant investment risks, including the possible loss of the principal amount invested. Past performance of investment products is not indicative of their future performance. Examples provided are for illustrative purposes only. While each of SGX and its affiliates (collectively, the “SGX Group Companies”) have taken reasonable care to ensure the accuracy and completeness of the information provided, each of the SGX Group Companies disclaims any and all guarantees, representations and warranties, expressed or implied, in relation to this document and shall not be responsible or liable (whether under contract, tort (including negligence) or otherwise) for any loss or damage of any kind (whether direct, indirect or consequential losses or other economic loss of any kind, including without limitation loss of profit, loss of reputation and loss of opportunity) suffered or incurred by any person due to any omission, error, inaccuracy, incompleteness, or otherwise, any reliance on such information, or arising from and/or in connection with this document. The information in this document may have been obtained via third party sources and which have not been independently verified by any SGX Group Company. No SGX Group Company endorses or shall be liable for the content of information provided by third parties. The SGX Group Companies may deal in investment products in the usual course of their business, and may be on the opposite side of any trades. SGX is an exempt financial adviser under the Financial Advisers Act (Cap. 110) of Singapore. The information in this document is subject to change without notice. This document shall not be reproduced, republished, uploaded, linked, posted, transmitted, adapted, copied, translated, modified, edited or otherwise displayed or distributed in any manner without SGX’s prior written consent.
